Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Acacia Research Completes Board Reconstitution, Appointing Isaac T. Kohlberg and Luis Rinaldini to Board of Directors



Reading Time: 5 minutes

Newly Reconstituted Board, With Exemplary Credentials and Deep IP
Experience, Reflects Milestone Achievement in Improved Corporate

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Acacia Research Corporation (Nasdaq: ACTG) today announced it has
appointed Isaac T. Kohlberg, Senior Associate Provost and Chief
Technology Development Officer at Harvard University, and Luis
Rinaldini, CEO of Groton Partners and former Vice Chairman and Global
Head of Telecom Mergers & Acquisitions at Credit Suisse First Boston, to
its Board of Directors (“Board”). These appointments complete the
rebuilding of Acacia’s Board and bring its membership to six directors.
C. Allen Bradley, Jr., who joined the Board in 2018, is resigning from
the Board having successfully led the reconstitution and strengthening
of Acacia’s Board. Newly elected Chairman Maureen O’Connell said, “With
a full Board now in place, we expect to quickly build out the management

Acacia Director Clifford Press said, “With Isaac and Luis’ additions the
Acacia Board of Directors now has an exemplary range of experience and
expertise in IP-related disciplines, including developing royalty
agreements and other commercialization structures.”

“Isaac Kohlberg’s distinguished career, including serving as Chief
Technology Development Officer at Harvard University, and deep
experience in the patent space make him a superb addition to the Board,”
said Acacia Director Al Tobia. “Isaac has been at the cutting edge of
the intellectual property world for many years and he has consistently
devoted his efforts to ensuring that new inventions result in broad
societal benefits. We look forward to drawing on his expertise,
especially his focus on creating mutually beneficial royalty agreements,
as we work to develop new models for investing in IP as an asset class.”

“I look forward to partnering with Acacia on developing its approach to
investing in and commercializing IP assets,” said Kohlberg. “Through my
work at Harvard and in prior roles, I have focused on finding ways to
partner with companies to ensure that new inventions and discoveries
have the broadest possible benefit for society as a whole.”

“We are also thrilled to have Luis Rinaldini, former Vice Chairman of
Credit Suisse and a long-time Senior Managing Director of Lazard’s
Technology, Media and Telecom group, join Acacia’s Board,” continued
Tobia. “With his impressive career and deep experience in finance,
technology and healthcare, and a particular emphasis on pharmaceutical
royalties, we know Luis will be a valuable addition to the Board.”

“I am excited to be a part of this new chapter for Acacia as it expands
its approach to investing in and commercializing IP assets,” said
Rinaldini. “Through my work at Groton Partners and in prior roles, I
have focused on acquisitions, divestitures, joint ventures and financing
of companies that depend heavily on innovation and intellectual

Clifford Press continued, “Allen Bradley stepped into his Board role
under exigent circumstances and provided a steadying hand for Acacia.
With his help, we have recruited a new, highly experienced and deeply
relevant Board with exceptionally qualified, independent individuals. On
behalf of the Board I’d like to thank Allen for his invaluable role in
this urgent and critically important effort, and thank him for his wise
guidance and insight throughout.”

Isaac T. Kohlberg Biography

Mr. Kohlberg has had a distinguished career protecting and
commercializing IP for leading universities and research institutions.
He currently is a Senior Associate Provost and Chief Technology
Development Officer at Harvard University, where he responsible for the
strategic management and commercial development of all technologies and
intellectual property (IP) arising from Harvard’s research enterprise.
Mr. Kohlberg’s role at Harvard University includes industry liaising and
outreach, IP management, business development, technology
commercialization and the formation of startup companies and new
ventures around Harvard technology platforms. In tandem, he is also
responsible for generating, structuring, and negotiating research
alliances and collaborations with industry and generating
industry-sponsored research funding for Harvard faculty.

Prior to joining Harvard in 2005, Isaac Kohlberg was the CEO of Tel Aviv
University’s Economic Corporation and head of Ramot, its technology
transfer organization. Prior to his role at Ramot, Mr. Kohlberg held
various roles at New York University (NYU), including Vice Provost, Vice
President for Industrial Liaison (NYU’s technology transfer program) and
headed the Office of Science and Technology Administration at NYU School
of Medicine. During his time at NYU, the institution entered into a
major licensing agreement to develop Remicade, a humanized monoclonal
antibody used in the treatment of Crohn’s Disease and other autoimmune
diseases, which led to one of the largest royalty revenue streams
generated by any university worldwide.

Before NYU, Mr. Kohlberg was the CEO of YEDA, the commercial arm of the
Weizmann Institute of Science in Israel. While at YEDA, Kohlberg
negotiated and concluded major royalty-bearing license agreements. Mr.
Kohlberg has served as a Director at Anchiano Therapeutics Ltd (TLV:
ANCN, NASDAQ: ANCN), a pivotal-stage biopharmaceutical company, since
2017 and as a Director at Clal Biotechnology Industries Ltd. (TLV: CBI),
a life sciences investment company, since 2015. Mr. Kohlberg received
his M.B.A. from INSEAD and LL.B. from Tel Aviv University.

Luis Rinaldini Biography

Luis E. Rinaldini has been CEO of Groton Partners since he founded the
firm in 2003. At Groton Partners, Mr. Rinaldini has advised Royalty
Pharma in over $1.5 billion of recapitalization transactions and
numerous royalty acquisitions. From 2001 to 2002, he was Vice Chairman
and Global Head of Telecom Mergers & Acquisitions at Credit Suisse First
Boston, based in London.

Mr. Rinaldini joined Credit Suisse First Boston from Lazard Frères,
where he served on the Executive Committee and was the Senior Managing
Director in charge of Telecom, within the Media, Technology and Telecom
Group as well as the firm’s Latin American practice.


Founded in 1993, Acacia Research Corporation (NASDAQ:ACTG) is an
industry leader in patent licensing and partners with inventors and
patent owners to unlock the financial value in their patented
inventions. Acacia bridges the gap between invention and application,
facilitating efficiency and delivering monetary rewards to the patent

Information about Acacia and its subsidiaries is available at

Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995

This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including the contributions of newly appointed director,
the appointment of additional directors, the ability to successfully
develop licensing programs and attract new business, rapid technological
change in relevant
 markets, changes in demand for current
and future intellectual property rights, legislative, regulatory and
competitive developments addressing licensing and enforcement of patents
and/or intellectual property in general, general economic conditions and
the success of our investments.
 Our Annual Report on Form
10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent
Current Reports on Form 8-K, and any amendments to the forgoing, and
other SEC filings discuss some of the important risk factors that may
affect our business, results of operations and financial condition.
undertake no obligation to revise or update publicly any forward-looking
statements for any reason. The results achieved in the most recent
quarter are not necessarily indicative of the results to be achieved by
us in any subsequent quarters, as it is currently anticipated that
Acacia Research Corporation’s financial results will vary, and may vary
significantly, from quarter to quarter.
 This variance is
expected to result from a number of factors, including risk factors
affecting our results of operations and financial condition referenced
above, and the particular structure of our licensing transactions, which
may impact the amount of inventor royalties and contingent legal
fees expenses we incur period to period.


Hayden IR
Rob Fink, 646-415-8972
[email protected]

Sloane & Company
Joe Germani / Kristen
Duarte, 212-486-9500
[email protected]
/ [email protected]

Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493


Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits




HERZLIYA, Israel and CALGARY, AB, Feb. 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the latest findings from the Company’s pharmacokinetic study of its LPT-CBD platform in rabbits.

The fundamentals of LPT-CBD lay in its ability to slowly release CBD into the blood stream. Studies conducted in various animal models including mice, dogs, goats, and sheep showed long pharmacokinetics of CBD that persisted up to several weeks. In the Company’s latest study conducted on rabbits, the results showed additional supportive data for the long exposure of CBD obtained following a single subcutaneous LPT-CBD injection.   

The Company is encouraged by these study results as they confirm the approach the Company is taking with its LPT platform. The results from studies of several organisms injected with the Company’s liposomal CBD –have consistently demonstrated that a detectable CBD level could be maintained for weeks following one injection. The Company will continue with human trials in the near future.

Pharmacokinetics (PK) is an important tool that helps evaluate the bioavailability and exposure level of a specific drug. Parameters such as maximal blood drug concentration (cMax), time to reach cMax (Tmax) and half-life of the drug are calculated based on data collected from blood analysis of the drug across a determined time. The collected PK parameters along with other tests help to define the required dose of a drug to achieve a maximal therapeutic effect. In the study conducted on rabbits, the animals were collected for blood analysis of the drug for up to 11 days. As expected, the animals presented a persistent CBD concentration in their blood that maintained through the entire testing period. This correlates to PK results obtained from other species, supporting the long CBD exposure and the necessity of only a single LPT-CBD injection to obtain a long and wide therapeutic window for CBD.   

About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales.

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025


Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.


Cision View original content:

Continue Reading


Schwazze Appoints Forrest Hoffmaster as Interim Chief Executive Officer




DENVER, Feb. 23, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) (“Schwazze” or the “Company”), today announced that Forrest Hoffmaster, the Company’s Chief Financial Officer, has been appointed to the additional role of interim Chief Executive Officer (“CEO”). This follows Nirup Krishnamurthy’s resignation as CEO and as a member of the Board of Directors (“Board”), effective February 20, 2024, due to personal reasons.

Mr. Hoffmaster, who joined the Company in January 2023, brings over 30 years of executive experience in finance and operations for both public and private companies. Prior to Schwazze, Mr. Hoffmaster served as CEO of New Seasons Market, a specialty gourmet food retailer, where he navigated the company through one of the most disruptive periods in the retail grocery industry. Under his leadership, Mr. Hoffmaster implemented a focused growth and cost optimization program, enabling the company to grow EBITDA by over 30% in two years. Prior to New Seasons Market, Forrest held leadership positions with other leading grocers including Whole Foods Market and H-E-B.

“Forrest is well-positioned to seamlessly step in and lead the Company’s day-to-day operations as we conduct our search for a permanent successor,” said Justin Dye, Chairman of the Board. “With Forrest’s proven track record and deep retail expertise, we plan to continue leveraging our operating playbook to drive strong Adjusted EBITDA margins and consistent cash flow generation. On behalf of the Board, I’d like to wish Nirup the best in his future endeavors.”

About Schwazze

Schwazze (OTCQX: SHWZ) (NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected] 

View original content:

Continue Reading


Hemp, Inc. Reports: Hemp-Based Foods Market Set to Reach $8.36 Billion by 2028



Continue Reading

Trending on Grassnews Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania